IGCS 2022
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting

Released: October 24, 2022

Expiration: October 23, 2023

Susana Banerjee
Susana Banerjee, MBBS, MA, PhD, FRCP

Activity

Progress
1
Course Completed

In this episode, Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:

  • Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer
  • Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer
  • Phase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancer
  • Retrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervix